Welcome to our dedicated page for Astrana Health SEC filings (Ticker: ASTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Astrana Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Astrana Health's regulatory disclosures and financial reporting.
Astrana Health, Inc. (ASTH) director David Schmidt reported a same-day option exercise and share disposition. He exercised 20,000 stock options for Common Stock at an exercise price of $5.00 per share, then disposed of 20,000 Common Shares to the issuer at $38.59 per share. The options were fully vested and exercisable, and following these transactions his holdings include 4,525 shares of restricted stock that vest on the earlier of June 10, 2027 or the 2027 annual meeting.
Astrana Health, Inc. reported initial beneficial ownership for executive John Vong, Senior Vice President – Accounting (PAO). He holds 22,426 shares of Common Stock directly, including 3,972 shares of restricted stock subject to future vesting and 584 shares acquired through the company’s Employee Stock Purchase Plan. The position also includes 3,104 and 2,156 restricted stock units that vest in scheduled semi-annual installments beginning in late 2026, contingent on continued employment.
Astrana Health, Inc. reported that former officer Glenn Sobotka surrendered 11,793 shares of unvested time-based and performance-based restricted common stock in a disposition to the issuer in connection with his retirement. Following this forfeiture, he holds 2,246 shares, including 1,300 restricted shares that will vest on an accelerated basis subject to his execution of a release of claims.
Astrana Health, Inc. reported substantial growth for the quarter and six months ended June 30, 2026. Quarterly capitation and other revenue rose to $972.5 million, with net income attributable to Astrana increasing to $19.7 million, or $0.40 basic and diluted EPS. For the first half of 2026, revenue reached $1.94 billion and net income attributable to Astrana was $34.2 million with diluted EPS of $0.69.
Total assets were $2.28 billion and total liabilities $1.68 billion, with stockholders’ equity at $830.2 million. Cash and cash equivalents stood at $400.8 million and total debt at $948.3 million, while operating activities generated $100.8 million of cash in the first half. Medical liabilities increased to $415.8 million, reflecting higher medical costs alongside growth in the business.
Astrana Health, Inc. reported strong results for the quarter ended June 30, 2026, with total revenue of $972.5 million, up 49% from a year earlier, driven primarily by capitation revenue. Net income attributable to Astrana increased to $19.7 million, and diluted EPS doubled to $0.40.
Non-GAAP performance was also robust: Adjusted EBITDA rose 43% to $68.9 million, maintaining a 7% margin, while adjusted diluted EPS reached a record-high $0.80. For the first half of 2026, free cash flow was $92.9 million on operating cash flow of $100.8 million.
The company raised its 2026 outlook, guiding to $3.8–$4.1 billion in revenue and $255–$280 million of Adjusted EBITDA, and expects free cash flow of $105–$132.5 million. Astrana highlighted its value-based model, with about 1.5 million patients and 81% of Q2 capitation revenue from full-risk arrangements. Management also refers to an existing material weakness in internal control over financial reporting and its intention to remediate it.
Vanguard Portfolio Management LLC, a Pennsylvania entity, reports beneficial ownership of 2,648,939 shares of Astrana Health Inc common stock on a Schedule 13G. This represents 5.34% of the class. Vanguard has sole voting power over 43,164 shares and sole dispositive power over all 2,648,939 shares, with no shared voting or dispositive power.
The position reflects securities held by Vanguard Portfolio Management LLC and specified affiliates, including Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC, for Vanguard funds and other managed accounts. Vanguard notes that no other individual person has an interest in more than 5% of the securities reported.
Astrana Health, Inc. reported that its accountable care organizations generated $120.4 million in gross shared savings in the 2024 performance year. All eight affiliated ACOs achieved net shared savings, including five in the Medicare Shared Savings Program and three in the ACO REACH model.
The company supports more than 20,000 providers caring for approximately 1.55 million patients through partnerships with over 20 payers nationwide. For the year ended December 31, 2025, Astrana recorded $3.18 billion in revenue, $24.1 million in net income, $123.1 million in EBITDA, and $205.4 million in Adjusted EBITDA. In the first quarter of 2026, revenue grew 56% year over year, reflecting continued expansion of its physician-centric, AI-enabled value-based care platform.
Astrana Health, Inc. announced that Chief Accounting Officer and principal accounting officer Glenn Sobotka will retire from his positions effective August 7, 2026. The company states his retirement is not due to any disagreement regarding operations, policies, or practices.
John Vong, currently Group Vice President, Accounting, has been appointed Senior Vice President – Accounting effective July 1, 2026 and will become principal accounting officer on August 7, 2026. Vong, age 52, has extensive prior experience in senior accounting roles at Astrana Health and Prospect Medical Systems. Effective July 1, 2026, his annual base salary will be $320,000. The company notes there are no related-party transactions or family relationships requiring disclosure.
Astrana Health, Inc. CEO and President Brandon Sim reported routine equity activity related to restricted stock vesting. He surrendered 1,093 shares of Common Stock at $44.51 per share to cover tax withholding obligations tied to vested restricted stock, a non-market, F-code tax-withholding disposition.
After this event, he directly holds 1,245,292 Common Stock shares, which include 34,207 unvested restricted shares and multiple tranches of restricted stock units scheduled to vest in semi-annual installments beginning in late 2026, plus 1,420 shares acquired under the Employee Stock Purchase Plan. Indirectly, trusts associated with Sim hold 392,816 and 258,824 shares, for which he disclaims beneficial ownership except for any pecuniary interest.
Schmidt David reported acquisition or exercise transactions in this Form 4 filing.
Astrana Health, Inc. director David Schmidt received a grant of 4,525 shares of restricted common stock as equity compensation. These shares were awarded at no cash cost to him under the company’s 2024 Equity Incentive Plan and will vest on the earlier of June 10, 2027 or the company’s 2027 annual meeting of stockholders. After this award, he holds a total of 36,019 common shares directly.